Full-Time

Control Room Manager

Posted on 11/23/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Birmingham, UK

In Person

Some UK travel required, with overnight stays and attendance at meetings outside normal hours.

Category
Operations & Logistics (2)
,
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Proven experience in warehouse control and management systems including automated technologies.
  • Experience in the pharmaceutical industry is highly preferred.
  • Proficiency in data analysis and performance metrics.
  • Customer and results-orientated with excellent communication skills and a positive, professional attitude.
  • Ability to work collaboratively and effectively across multiple functional departments.
  • Strong organisational skills to manage time, tasks, and resources effectively, ensuring deadlines and targets are met.
  • Ability to lead and motivate a team (including managers/leaders) in a fast-paced environment.
  • Advanced computer skills, including Microsoft Office 365 applications.
  • Excellent analytical, attention to detail and problem-solving skills, including the ability to deal with ambiguity.
  • Demonstrated ability to prioritise and multi-task various and conflicting responsibilities.
  • Ability to work in a warehouse environment, including standing and walking for extended periods.
  • Ability to lift and move materials as needed. We have a "lead by example" culture, and as such, you might be expected to carry out manual work occasionally.
  • Comfortable working in varying temperatures within the warehouse environment.
  • Strong communication and interpersonal skills.
Responsibilities
  • Provide core shift management of the Knapp and Manhattan warehouse management systems, ensuring seamless operation and minimal downtime.
  • Monitor the system to ensure optimum throughput and system availability, identifying when performance deviates from target or acceptable levels.
  • Coordinate with IT and other departments to resolve system issues promptly and efficiently.
  • Manage, lead, and motivate a specialist team of direct reports, providing 24/7 cover, and oversee to Operational teams, to ensure the efficient running of all automation systems.
  • Foster a positive and collaborative work environment, encouraging teamwork and promoting continuous improvement and development.
  • Ensure direct reports foster a positive team culture by promoting teamwork, collaboration, building morale and continuous learning.
  • Assist the team with resolving complex issues, ensuring the highest quality standards.
  • Provide ongoing training and development opportunities for team members to enhance their skills and knowledge.
  • Embrace and set a good example in the everyday, a culture that supports the company’s Guiding principles.
  • Monitor the daily workload progress and take any systems, engineering, or operational actions necessary to ensure the work is completed on time.
  • Track, monitor, and make decisions to adjust the outbound flow, including tactical workload reduction to ensure that all vehicles are loaded on time to meet the trunking delivery schedule.
  • Assess the balance of the day's inputs and outputs to make decisions on required actions to ensure maximum fulfilment of all orders.
  • Control all pick planning and re-profiling activity and associated pick resource estimates for the relevant areas to ensure maximum service level and efficiency within those warehouse areas.
  • Coordinate and drive engineering and system expertise to rectify issues at the earliest opportunity.
  • Analyse issues post-resolution to accurately conclude the root cause and develop a clear action plan for resolution.
  • Ensure issues and their resolution are documented accurately, and best practices are shared within the network.
  • Prepare and present regular reports on system performance and issue resolution to senior management.
  • Communicate effectively with all levels of the organisation, providing updates on system performance and operational status.
  • Prepare and present regular reports on system performance, operational efficiency, and team performance.
  • Ensure department SOPs and KPIs are met to drive performance against service, compliance, productivity and cost in line with targets. Implement actions to reverse identified areas of under-performance.
  • Champion the health and safety culture which ensures safe processes, procedures and behaviours as well as continuous improvement through best practice activities.
  • Ensure a culture of being safe, legal, compliant and continuous improvement.
  • Conduct regular audits and inspections working with the H&S leader to maintain compliance and address any deficiencies.
  • To deliver operational strategy through effective communication and a proactive approach to the management of automation.
  • Ensure that all Service Level agreements (SLAs) are met.
  • Proactively seek innovative solutions and methodologies to ensure that the full potential of the system is realised.
  • Oversight of technical resource development will involve creating long-term strategic plans to guarantee efficient and cost-effective solutions.
  • Experience with Manhattan and/or Knapp
  • Knowledge of regulatory compliance and quality standards in pharmaceutical distribution.
  • Experience working in a highly regulated and audited environment, ensuring compliance with all standards.
  • Manual Handling: Manual handling tasks, such as lifting and bending, are a part of this role.
Desired Qualifications
  • Experience with Manhattan and/or Knapp
  • Knowledge of regulatory compliance and quality standards in pharmaceutical distribution.
  • Experience working in a highly regulated and audited environment, ensuring compliance with all standards.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE